Back | Next |
home / stock / phvs / phvs message board
Subject | By | Source | When |
---|---|---|---|
Agree best to wait for pop tomorrow then | doebop | investorshub | 12/09/2022 3:22:15 AM |
Actually Hereditary Angioedema is very hard to treat. | Laster | investorshub | 12/09/2022 1:49:22 AM |
Short can't short cuz this going to 20-30 | Pt3 | investorshub | 12/09/2022 1:31:13 AM |
They will short this down tomorrow | winna | investorshub | 12/08/2022 11:49:45 PM |
Dude your so screwed if you dont cover | MT101 | investorshub | 12/08/2022 11:29:07 PM |
Watch out for RED INK tomorrow, behind this | Invest-in-America | investorshub | 12/08/2022 11:07:35 PM |
$PHVS: My post is the TRUTH, Dude; if | Invest-in-America | investorshub | 12/08/2022 11:03:16 PM |
False. I recommend you cover your short or | MT101 | investorshub | 12/08/2022 10:56:12 PM |
$PHVS: Price SOARED today, & all behind the | Invest-in-America | investorshub | 12/08/2022 10:23:37 PM |
Thats good. I loaded 3k shares here around | MT101 | investorshub | 12/08/2022 7:01:57 PM |
Got me 2,5 k shares just now below | europtiger | investorshub | 12/08/2022 6:58:50 PM |
Going to $20-30 range | MT101 | investorshub | 12/08/2022 6:53:52 PM |
This stock has sure gone crazy! LMAO all | subslover | investorshub | 12/08/2022 6:48:01 PM |
PHVS: Indeed!!! NOT even that, per se --- | Invest-in-America | investorshub | 12/08/2022 6:36:47 PM |
HALTED for the 3rd time at 1;30 PM | subslover | investorshub | 12/08/2022 6:31:17 PM |
$10.00 just breached. | subslover | investorshub | 12/08/2022 6:27:22 PM |
They will short this big time | winna | investorshub | 12/08/2022 6:25:08 PM |
This big move is from phase 2 results? | Cosa | investorshub | 12/08/2022 6:16:29 PM |
Trading resumed at 12:30 pm @ $7.50. What | subslover | investorshub | 12/08/2022 5:35:00 PM |
Yes, that'll work..... | davidsson10 | investorshub | 12/08/2022 5:33:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyk...
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation ...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks Executing from a strong financial position with cash a...